Table 1 Prevalence rates of pfdhfr/pfdhps mutant parasites during the course of pregnancy, by treatment group.

SP

pfdhfr 51

53/57

18/18

28/28

pfdhfr 59

45/54

17/20

20/27

pfdhfr 108

54/59

21/21

28/29

pfdhfr 164

0/50

0/15

0/19

pfdhfr triple mutants*

43/53

16/18

19/27

pfdhps 437

52/55

21/22

27/27

pfdhps 540

0/62

0/22

0/28

pfdhfr/pfdhps quadruple mutants**

37/49

16/18

16/22

MQ

pfdhfr 51

44/47

9/9

10/11

pfdhfr 59

40/43

7/8

10/11

pfdhfr 108

46/47

9/9

11/11

pfdhfr 164

0/41

0/8

0/9

pfdhfr triple mutants*

39/43

7/8

8/11

pfdhps 437

39/43

6/7

10/10

pfdhps 540

0/47

0/8

0/9

pfdhfr/pfdhps quadruple mutants*

34/42

4/6

7/10